A $2 Billion Reason Why AstraZeneca Stock Is Down Today

AstraZeneca (AZN) stock came under pressure on Sept. 29 after the pharma giant announced a massive $2 billion investment in Summit Therapeutics (SMMT). As investors responded to the disclosure, AZN was briefly seen trading below its 20-day and 50-day moving averages (MAs), indicating bears are attempting to regain control in the near term. 

Versus the start of 2026, AstraZeneca shares are down nearly 10% at the time of writing. 

Why AstraZeneca Stock Slipped Today?

AstraZeneca’s strategic investment in Summit is aimed at accelerating development of ivonescimab, a promising bispecific antibody cancer therapy. 

Under the agreement, the British multinational will purchase Summit’s convertible preferred stock, securing a 12% stake in the biotech firm. 

Plus, AZN has agreed to joint global clinical trials combining ivonescimab with its own oncology treatments, including antibody-drug conjugates

While the deal solidifies AstraZeneca’s pipeline, the steep cash outlay disappointed investors who wanted the company to spend that money on internal R&D, buybacks, or debt reduction. 

Should You Buy the Dip in AZN Shares?

For long-term investors, today’s pullback in AZN stock presents a compelling buying opportunity. 

The NYSE-listed firm currently trades at a forward price-to-earnings (P/E) multiple of under 18x, meaningfully below its historical averages, while paying a healthy 1.96% dividend yield as well. 

Crucially, the Summit deal reinforces AstraZeneca’s dominance in oncology and positions it to capture substantial market share in next-generation cancer immunotherapies. 

Beyond oncology, AZN also boasts a deep late-stage pipeline spanning rare diseases, cardiovascular care, and next-generation obesity treatments. 

Backed by double-digit core earnings per share (EPS) growth and an ambitious target to hit $80 billion in annual sales by the end of this decade, AstraZeneca offers resilient long-term fundamental strength.

While October is historically muted for AZN, it tends to close both November and December in the green — a seasonal trend that further improves its near-term appeal. 

What’s the Consensus Rating on AstraZeneca?

Wall Street analysts also recommend sticking with AstraZeneca stock for the long term. 

According to Barchart, the consensus rating on AZN sits at “Strong Buy,” with the mean price target of nearly $204 indicating potential upside of roughly 25% from here. 

On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.